Masaya Kubota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masaya Kubota has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Hideki Ishikawa
Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan
1 shared publication Hisashi Nakamura
Akasaka Endoscopic Clinic, Tokyo, Japan
1 shared publicationJiro Nakamoto
Department of Gastroenterology, Tokushima Prefectural Hospital, Tokushima, Japan
1 shared publication- Kaizo Kagemoto
Department of Gastroenterology and Oncology Institute of Biomedical Sciences Tokushima University Graduate School Tokushima Japan
1 shared publication - Keita Harada
Department of Gastroenterology Okayama University Hospital Okayama Japan
1 shared publication Koichi Kawabe
Department of Gastroenterology, Fukaya Red Cross Hospital, Saitama, Japan
1 shared publication
Latest Publications
- 28 August 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
INTRODUCTION: Experimental and limited clinical studies suggest that curcumin has chemopreventive activity in the colorectum. This large-scale clinical trial evaluated the efficacy and safety of curcumin in patients with previously endoscopically resected colorectal neoplasia. METHODS: This randomized, double-blind, placebo-controlled multicenter trial enrolled patients with previously resected colorectal neoplasia. Eligible patients were randomly assigned (1:1), using a stratified, computer-generated scheme to receive oral submicron-powdered curcumin (Theracurmin; 180 mg twice daily) or identical placebo capsules for 2 years. All analyses were performed according to a modified intention-to-treat principle including all randomly assigned patients who underwent the 2-year colonoscopy. RESULTS: Between April 1, 2016, and March 31, 2020, 577 patients were randomly assigned to curcumin (n = 287) or placebo groups (n = 290). The detection rate of recurrent colorectal adenomas at 2 years, the primary end point, did not differ significantly between groups (risk ratio 0.98; 95% confident interval 0.82–1.16). However, the detection rate of adenomas ≥6 mm, a prespecified lesion category recommended for endoscopic resection in Japanese guidelines, was significantly lower with curcumin (risk ratio, 0.56; 95% confident interval, 0.33–0.95; P = 0.04). The per-patient number of adenomas ≥6 mm was also significantly lower ( P = 0.03), and the median size of all detected adenomas was significantly smaller in the curcumin group ( P = 0.003). The inhibitory effect seemed more pronounced in patients with higher baseline adenoma burden and in men in exploratory analyses. Treatment-related adverse events were infrequent and mild. DISCUSSION: Curcumin inhibited the growth of recurrent colorectal adenomas, despite no significant reduction in the overall incidence of recurrence. This is the first large-scale randomized clinical trial demonstrating the suppressive efficacy of curcumin against colorectal neoplasia, and also highlighting the importance of incorporating growth-related endpoints, in addition to incidence-based or detection-based end points, in chemoprevention studies (jRCTs061180079).
- 28 August 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
INTRODUCTION: Experimental and limited clinical studies suggest that curcumin has chemopreventive activity in the colorectum. This large-scale clinical trial evaluated the efficacy and safety of curcumin in patients with previously endoscopically resected colorectal neoplasia. METHODS: This randomized, double-blind, placebo-controlled multicenter trial enrolled patients with previously resected colorectal neoplasia. Eligible patients were randomly assigned (1:1), using a stratified, computer-generated scheme to receive oral submicron-powdered curcumin (Theracurmin; 180 mg twice daily) or identical placebo capsules for 2 years. All analyses were performed according to a modified intention-to-treat principle including all randomly assigned patients who underwent the 2-year colonoscopy. RESULTS: Between April 1, 2016, and March 31, 2020, 577 patients were randomly assigned to curcumin (n = 287) or placebo groups (n = 290). The detection rate of recurrent colorectal adenomas at 2 years, the primary end point, did not differ significantly between groups (risk ratio 0.98; 95% confident interval 0.82–1.16). However, the detection rate of adenomas ≥6 mm, a prespecified lesion category recommended for endoscopic resection in Japanese guidelines, was significantly lower with curcumin (risk ratio, 0.56; 95% confident interval, 0.33–0.95; P = 0.04). The per-patient number of adenomas ≥6 mm was also significantly lower ( P = 0.03), and the median size of all detected adenomas was significantly smaller in the curcumin group ( P = 0.003). The inhibitory effect seemed more pronounced in patients with higher baseline adenoma burden and in men in exploratory analyses. Treatment-related adverse events were infrequent and mild. DISCUSSION: Curcumin inhibited the growth of recurrent colorectal adenomas, despite no significant reduction in the overall incidence of recurrence. This is the first large-scale randomized clinical trial demonstrating the suppressive efficacy of curcumin against colorectal neoplasia, and also highlighting the importance of incorporating growth-related endpoints, in addition to incidence-based or detection-based end points, in chemoprevention studies (jRCTs061180079).